@article{LoefflerLoefflerKobsaretal.2015,
  author    = {Loeffler, Claudia and Loeffler, J{\"u}rgen and Kobsar, Anna and Speer, Christian P. and Eigenthaler, Martin},
  title     = {Septic Vs Colonizing Group B Streptococci Differentially Regulate Inflammation and Apoptosis in Human Coronary Artery Endothelial Cells - a Pilot Study},
  series = {Journal of Pediatrics and Neonatal Care},
  volume    = {2},
  journal   = {Journal of Pediatrics and Neonatal Care},
  number    = {2},
  doi       = {10.15406/jpnc.2015.02.00064},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125596},
  pages     = {00064},
  year      = {2015},
  abstract  = {In this pilot study, we exemplify differences between a septic and a colonizing GBS strain during their interaction with Endothelial Cells by evaluating cytokine levels, surface and apoptosis-related molecules. These preliminary results indicate that in vitro infection using an exemplary septic GBS strain results in diminished activation of the innate immune response.},
  language  = {en}
}
@article{OrthCazesButtetal.2015,
  author    = {Orth, Martin F. and Cazes, Alex and Butt, Elke and Grunewald, Thomas G. P.},
  title     = {An update on the LIM and SH3 domain protein 1 (LASP1): a versatile structural, signaling, and biomarker protein},
  series = {Oncotarget},
  volume    = {6},
  journal   = {Oncotarget},
  number    = {1},
  doi       = {10.18632/oncotarget.3083},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-144546},
  pages     = {26-42},
  year      = {2015},
  abstract  = {The gene encoding the LIM and SH3 domain protein (LASP1) was cloned two decades ago from a cDNA library of breast cancer metastases. As the first protein of a class comprising one N-terminal LIM and one C-terminal SH3 domain, LASP1 founded a new LIM-protein subfamily of the nebulin group. Since its discovery LASP1 proved to be an extremely versatile protein because of its exceptional structure allowing interaction with various binding partners, its ubiquitous expression in normal tissues, albeit with distinct expression patterns, and its ability to transmit signals from the cytoplasm into the nucleus. As a result, LASP1 plays key roles in cell structure, physiological processes, and cell signaling. Furthermore, LASP1 overexpression contributes to cancer aggressiveness hinting to a potential value of LASP1 as a cancer biomarker. In this review we summarize published data on structure, regulation, function, and expression pattern of LASP1, with a focus on its role in human cancer and as a biomarker protein. In addition, we provide a comprehensive transcriptome analysis of published microarrays (n=2,780) that illustrates the expression profile of LASP1 in normal tissues and its overexpression in a broad range of human cancer entities.},
  language  = {en}
}
@article{SchuetzeRoehringVorlovaetal.2015,
  author    = {Sch{\"u}tze, Friedrich and R{\"o}hring, Florian and Vorlov{\´a}, Sandra and G{\"a}tzner, Sabine and Kuhn, Anja and Erg{\"u}n, S{\"u}leyman and Henke, Erik},
  title     = {Inhibition of lysyl oxidases improves drug diffusion and increases efficacy of cytotoxic treatment in 3D tumor models},
  series = {Scientific Reports},
  volume    = {5},
  journal   = {Scientific Reports},
  number    = {17576},
  doi       = {10.1038/srep17576},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-145109},
  year      = {2015},
  abstract  = {Tumors are characterized by a rigid, highly cross-linked extracellular matrix (ECM), which impedes homogeneous drug distribution and potentially protects malignant cells from exposure to therapeutics. Lysyl oxidases are major contributors to tissue stiffness and the elevated expression of these enzymes observed in most cancers might influence drug distribution and efficacy. We examined the effect of lysyl oxidases on drug distribution and efficacy in 3D in vitro assay systems. In our experiments elevated lysyl oxidase activity was responsible for reduced drug diffusion under hypoxic conditions and consequently impaired cytotoxicity of various chemotherapeutics. This effect was only observed in 3D settings but not in 2D-cell culture, confirming that lysyl oxidases affect drug efficacy by modification of the ECM and do not confer a direct desensitizing effect. Both drug diffusion and efficacy were strongly enhanced by inhibition of lysyl oxidases. The results from the in vitro experiments correlated with tumor drug distribution in vivo, and predicted response to therapeutics in murine tumor models. Our results demonstrate that lysyl oxidase activity modulates the physical barrier function of ECM for small molecule drugs influencing their therapeutic efficacy. Targeting this process has the potential to significantly enhance therapeutic efficacy in the treatment of malignant diseases.},
  language  = {en}
}
@article{VamanVSPoppeHoubenetal.2015,
  author    = {Vaman V. S., Anjana and Poppe, Heiko and Houben, Roland and Grunewald, Thomas G. P. and Goebeler, Matthias and Butt, Elke},
  title     = {LASP1, a Newly Identified Melanocytic Protein with a Possible Role in Melanin Release, but Not in Melanoma Progression},
  series = {PLoS One},
  volume    = {10},
  journal   = {PLoS One},
  number    = {6},
  doi       = {10.1371/journal.pone.0129219},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125994},
  pages     = {e0129219},
  year      = {2015},
  abstract  = {The LIM and SH3 protein 1 (LASP1) is a focal adhesion protein. Its expression is increased in many malignant tumors. However, little is known about the physiological role of the protein. In the present study, we investigated the expression and function of LASP1 in normal skin, melanocytic nevi and malignant melanoma. In normal skin, a distinct LASP1 expression is visible only in the basal epidermal layer while in nevi LASP1 protein is detected in all melanocytes. Melanoma exhibit no increase in LASP1 mRNA compared to normal skin. In melanocytes, the protein is bound to dynamin and mainly localized at late melanosomes along the edges and at the tips of the cell. Knockdown of LASP1 results in increased melanin concentration in the cells. Collectively, we identified LASP1 as a hitherto unknown protein in melanocytes and as novel partner of dynamin in the physiological process of membrane constriction and melanosome vesicle release.},
  language  = {en}
}